What is HC Wainwright’s Forecast for PSTV FY2027 Earnings?

Plus Therapeutics, Inc. (NASDAQ:PSTV) – Equities research analysts at HC Wainwright dropped their FY2027 earnings estimates for shares of Plus Therapeutics in a report issued on Wednesday, November 26th. HC Wainwright analyst S. Lee now forecasts that the company will post earnings of ($0.14) per share for the year, down from their previous estimate of ($0.06). HC Wainwright currently has a “Buy” rating and a $2.00 target price on the stock. The consensus estimate for Plus Therapeutics’ current full-year earnings is ($2.30) per share. HC Wainwright also issued estimates for Plus Therapeutics’ FY2028 earnings at $0.00 EPS and FY2029 earnings at $0.23 EPS.

Plus Therapeutics (NASDAQ:PSTV) last released its quarterly earnings data on Thursday, October 30th. The company reported ($0.04) earnings per share for the quarter, missing the consensus estimate of ($0.02) by ($0.02). The company had revenue of $1.40 million for the quarter, compared to analysts’ expectations of $1.50 million.

PSTV has been the subject of a number of other research reports. Weiss Ratings restated a “sell (e+)” rating on shares of Plus Therapeutics in a research report on Wednesday, October 8th. Wall Street Zen raised shares of Plus Therapeutics from a “strong sell” rating to a “hold” rating in a report on Saturday, August 16th. Zacks Research lowered shares of Plus Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, November 11th. Maxim Group cut their price objective on shares of Plus Therapeutics from $4.00 to $3.00 and set a “buy” rating on the stock in a research report on Monday, August 18th. Finally, D Boral Capital raised shares of Plus Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, September 3rd. One analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Plus Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $7.25.

Plus Therapeutics Trading Up 2.8%

NASDAQ:PSTV opened at $0.62 on Monday. The stock has a 50 day moving average of $0.60 and a 200-day moving average of $0.48. The firm has a market capitalization of $84.52 million, a PE ratio of -0.27 and a beta of 0.77. Plus Therapeutics has a 52 week low of $0.16 and a 52 week high of $2.31.

Hedge Funds Weigh In On Plus Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Virtu Financial LLC acquired a new position in shares of Plus Therapeutics during the 1st quarter valued at $38,000. Jane Street Group LLC bought a new position in Plus Therapeutics during the second quarter valued at about $41,000. Susquehanna International Group LLP bought a new position in Plus Therapeutics during the third quarter valued at about $46,000. Scientech Research LLC acquired a new position in Plus Therapeutics during the third quarter worth about $100,000. Finally, Altium Capital Management LLC bought a new stake in Plus Therapeutics in the third quarter worth about $628,000. 3.28% of the stock is owned by institutional investors.

About Plus Therapeutics

Plus Therapeutics, Inc, a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. Its lead radiotherapeutic drug candidate is rhenium (186Re) obisbemeda, a patented radiotherapy that targets central nervous system cancers and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers.